Knight Therapeutics (TSE:GUD)‘s stock had its “accumulate” rating restated by research analysts at Bloom Burton in a research note issued to investors on Friday.
GUD has been the subject of several other reports. Raymond James set a C$10.25 price objective on Knight Therapeutics and gave the company an “outperform” rating in a research note on Thursday, July 12th. TD Securities raised their target price on Knight Therapeutics from C$9.50 to C$10.00 in a research note on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of C$10.15.
Shares of GUD stock opened at C$8.30 on Friday. Knight Therapeutics has a 1-year low of C$7.38 and a 1-year high of C$8.81.
Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, November 8th. The company reported C$0.03 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of C$0.03. The firm had revenue of C$3.22 million during the quarter, compared to analyst estimates of C$2.26 million. On average, equities analysts predict that Knight Therapeutics will post 0.130000001435583 earnings per share for the current fiscal year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Further Reading: Why do company’s buyback their stock?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.